Characterising The Muscarinic Receptor Deficit In Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$476,543.00
Summary
Post-mortem examination of the brains of schizophrenia patients reveals a substantial loss of muscarinic receptors. This is likely to be clinically very important if it can also be confirmed in living patients. Having developed a new scanning technique that shows muscarinic receptors in the living brain, we will now scan patients with schizophrenia to see if they also show this receptor loss, and see how it affects them. This could open new doors to understanding and treating the disease.
Food And Water For Life: Co-creation And Evaluation Of Sustainable Innovations To Strengthen Food And Water Security
Funder
National Health and Medical Research Council
Funding Amount
$1,169,419.00
Summary
Aboriginal and Torres Strait Islander peoples suffer a disproportionate burden of non-communicable diseases. Poor diets, exacerbated by low quality water supplies, are one of the biggest contributors to this. Through our existing long-standing partnership, his project will establish a framework and use regulatory analysis to support the Aboriginal community in Walgett to develop a transformative community-led food and water security action plan to improve the long-term health and well-being.
Working With Horses To Promote The Wellbeing Of Aboriginal Youth: An Experiential Learning Approach For The Kimberley
Funder
National Health and Medical Research Council
Funding Amount
$2,516,797.00
Summary
This project aims to implement an Aboriginal-led Equine-Assisted Learning (EAL) program in multiple locations across the Kimberley to enhance the social and emotional wellbeing of Aboriginal youth. EAL is a learning approach where participants learn important life skills by 'doing' activities with horses. These activities enhance problem-solving skills, communication, selfâawareness, and emotional regulation by engaging multiple brain systems, which can help cope with disruptive life stressors.
Novel Genomic Approaches To Identify The Missing Genetics Underlying Skeletal Muscle Disease.
Funder
National Health and Medical Research Council
Funding Amount
$1,935,965.00
Summary
Skeletal muscle diseases can result in death in infancy or cause life-long and significant physical disability. Many families do not have a genetic explanation for their condition. We will use established and new technologies to find the missing genetics causing these devastating diseases. Our work has world-wide impact for the patients and families affected by these diseases.
Host Targeted Adjunctive Therapies To Boost Antimalarial Immunity
Funder
National Health and Medical Research Council
Funding Amount
$2,060,189.00
Summary
Malaria caused 200 million cases and 400000 deaths in 2018. One problem in developing new control strategies for malaria is that following a malaria infection, individuals develop disruptive immune responses that block vaccines. Our project investigates the ability of a repurposed drug to prevent the development of disruptive immune responses during malaria in humans. Results of our studies will inform the development of new malaria control tools.
A Practice Change For Patients With Severe Chronic, Clinically Unexplained Gastrointestinal Symptoms: A Randomised, Controlled Intervention To Assess Efficacy And Cost-effectiveness
Funder
National Health and Medical Research Council
Funding Amount
$1,276,080.00
Summary
Unexplained chronic gastrointestinal symptoms are extremely common and costly to the health system. Currently patients are managed in the hospital setting with the 'typical' face-to-face office-based model which sees the clinician spending valuable time gathering information and often treatments (e.g. allied health) delivered in a non-standard way. This project will evaluate the effectiveness of a new standard best-practice clinical model with a structured technology enabled management approach.
Determining The Molecular Basis Of Therapy Resistance Conferred By Genetic Lesions In The Tumour Protein TP53 In Haematological Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$885,183.00
Summary
Blood cancers that have genetic lesions in a tumour suppressor protein called TP53 respond poorly to therapy. Curing these patients is extremely challenging and new therapeutic strategies are desperately needed. Here, we aim to uncover the molecular mechanisms of drug resistance caused by loss of TP53 function and rationally design new therapies that may be curative. To do this, our team of leading scientists and clinicians will study patient samples and pre-clinical models of blood cancer.